Media stories about Cempra (NASDAQ:CEMP) have been trending somewhat positive recently, according to AlphaOne Sentiment Analysis. The research group, a subsidiary of Accern, identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cempra earned a news impact score of 0.09 on AlphaOne’s scale. AlphaOne also gave press coverage about the biotechnology company an impact score of 89 out of 100, meaning that recent news coverage is very likely to have an impact on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Alpha One’s analysis:
- Angie`s List Inc (ANGI), Cempra Inc (CEMP) Shares Moving On Volume – Stock Daily Review (stockdailyreview.com)
- Cempra, Inc. (NASDAQ:CEMP) Trading Up – Short Interest decreased by -7.42% – Highlight Press (highlightpress.com)
- Cempra Inc (CEMP) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- Zacks: Analysts Expect Cempra Inc (CEMP) to Announce -$0.32 EPS (americanbankingnews.com)
- Cempra Inc (CEMP) Stock Rating Lowered by ValuEngine (americanbankingnews.com)
Cempra (NASDAQ:CEMP) traded up 0.641% on Thursday, reaching $3.925. The company’s stock had a trading volume of 292,990 shares. The company’s market cap is $206.07 million. The firm’s 50-day moving average price is $3.89 and its 200 day moving average price is $4.23. Cempra has a 52-week low of $2.55 and a 52-week high of $26.95.
Cempra (NASDAQ:CEMP) last issued its quarterly earnings data on Friday, April 28th. The biotechnology company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.16. The firm had revenue of $4.87 million during the quarter, compared to the consensus estimate of $3.55 million. Cempra had a negative return on equity of 59.94% and a negative net margin of 678.72%. During the same period in the prior year, the business posted ($0.61) earnings per share. Equities analysts anticipate that Cempra will post ($1.06) EPS for the current fiscal year.
CEMP has been the topic of several recent research reports. Roth Capital upgraded Cempra from a “neutral” rating to a “buy” rating and decreased their price target for the company from $8.00 to $2.50 in a report on Monday, February 27th. Vetr lowered Cempra from a “strong-buy” rating to a “buy” rating and set a $3.43 target price on the stock. in a research note on Tuesday, February 21st. Zacks Investment Research raised Cempra from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Tuesday, May 2nd. Stifel Nicolaus reissued a “hold” rating and issued a $4.00 target price on shares of Cempra in a research note on Wednesday, March 1st. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $3.00 target price on shares of Cempra in a research note on Thursday, May 25th. Four research analysts have rated the stock with a sell rating, ten have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $11.34.
ILLEGAL ACTIVITY WARNING: This article was originally published by Mideast Time and is the property of of Mideast Time. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.mideasttime.com/cempra-cemp-receives-daily-news-impact-score-of-0-09/1763823.html.
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc and related companies with MarketBeat.com's FREE daily email newsletter.